Literature DB >> 21644044

The role of human xanthine oxidoreductase (HXOR), anti-HXOR antibodies, and microorganisms in synovial fluid of patients with joint inflammation.

Najah Al-Muhtaseb1, Elham Al-Kaissi, Abdul Jalil Thawaini, Zuhair Muhi Eldeen, Sabah Al-Muhtaseb, Badiee Al-Saleh.   

Abstract

This work is to investigate the levels of human xanthine oxidoreductase (HXOR), its antibodies, and microorganisms in synovial fluid of patients with untreated rheumatoid joint diseases. Synovial fluids were collected from sixty-four patients with rheumatoid joint diseases. Sixty-four age-matched individuals were included as control. Xanthine oxidoreductase (XOR) proteins level and anti-XOR antibodies were determined in the blood and synovial fluid, using human XOR as antigen, by enzyme-linked immunosorbent (ELISA) assay. Synovial fluids were cultured for bacteria and fungi. The titers of XOR protein in the synovial fluid of patients with rheumatoid arthritis were 90.43 ± 23.37 μg/ml (mean ± SD, n = 29) and up to 62.42 ± 8.74 μg/ml (mean ± SD, n = 35) in other joint inflammation. Anti-HXOR antibodies titers in patients were 167.72 ± 23.64 μg/ml, n = 64, which was significantly higher in rheumatoid arthritis patients. The results indicated that anti-HXOR antibodies in synovial fluids have a protective role as high concentrations against XOR were detected in inflammatory arthritis. These antibodies play a role in eliminating XOR from synovial fluids. However, immune complex formation could activate complement and participate in propagating the inflammatory cycle. Synovial aspirate ordinary microbial cultures were negative for any bacteria or fungi, but that does not exclude organisms of special culture requirements.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21644044     DOI: 10.1007/s00296-011-1965-0

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  54 in total

1.  Do we still miss the chance of effectively treating early rheumatoid arthritis? New answers from a new study.

Authors:  S Kary; J Fritz; H U Scherer; G R Burmester
Journal:  Rheumatology (Oxford)       Date:  2004-06-08       Impact factor: 7.580

Review 2.  Role of xanthine oxidoreductase as an antimicrobial agent.

Authors:  Hannah M Martin; John T Hancock; Vyv Salisbury; Roger Harrison
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

Review 3.  Human T cell leukemia virus type-I and rheumatoid arthritis.

Authors:  T Hasunuma; T Sumida; K Nishioka
Journal:  Int Rev Immunol       Date:  1998       Impact factor: 5.311

Review 4.  The immunopathology of joint inflammation in rheumatoid arthritis.

Authors:  N J Zvaifler
Journal:  Adv Immunol       Date:  1973       Impact factor: 3.543

Review 5.  Xanthine oxidase: biochemistry, distribution and physiology.

Authors:  D A Parks; D N Granger
Journal:  Acta Physiol Scand Suppl       Date:  1986

Review 6.  Reactive oxygen species as cellular messengers.

Authors:  A U Khan; T Wilson
Journal:  Chem Biol       Date:  1995-07

7.  Determination of human plasma xanthine oxidase activity by high-performance liquid chromatography.

Authors:  T Yamamoto; Y Moriwaki; S Takahashi; Z Tsutsumi; J Yamakita; Y Nasako; K Hiroishi; K Higashino
Journal:  J Chromatogr B Biomed Appl       Date:  1996-06-07

Review 8.  Structure and function of xanthine oxidoreductase: where are we now?

Authors:  Roger Harrison
Journal:  Free Radic Biol Med       Date:  2002-09-15       Impact factor: 7.376

9.  Anti-xanthine oxidase antibodies in sera and synovial fluid of patients with rheumatoid arthritis and other joint inflammations.

Authors:  Lekhmici Arrar; Nadjet Hanachi; Khaled Rouba; Noureddine Charef; Seddik Khennouf; Abderrahmane Baghiani
Journal:  Saudi Med J       Date:  2008-06       Impact factor: 1.484

Review 10.  The physiology of endothelial xanthine oxidase: from urate catabolism to reperfusion injury to inflammatory signal transduction.

Authors:  Avedis Meneshian; Gregory B Bulkley
Journal:  Microcirculation       Date:  2002-07       Impact factor: 2.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.